URGN vs. NKTR
URGN (UroGen Pharma Ltd.) and NKTR (Nektar Therapeutics) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, URGN returned 15.86%/yr vs -23.46%/yr for NKTR. At a 0.26 correlation, their price movements are largely independent.
Performance
URGN vs. NKTR - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, URGN achieves a 49.40% return, which is significantly lower than NKTR's 55.39% return.
URGN
- 1D
- 4.23%
- 1M
- 21.11%
- YTD
- 49.40%
- 6M
- 48.39%
- 1Y
- 138.84%
- 3Y*
- 45.07%
- 5Y*
- 15.86%
- 10Y*
- —
NKTR
- 1D
- 7.74%
- 1M
- -1.37%
- YTD
- 55.39%
- 6M
- 51.10%
- 1Y
- 672.03%
- 3Y*
- 96.12%
- 5Y*
- -23.46%
- 10Y*
- -11.21%
URGN vs. NKTR - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
URGN UroGen Pharma Ltd. | 49.40% | 119.91% | -29.00% | 69.11% | -6.73% | -47.23% | -46.00% | -22.50% | 15.72% | 179.98% |
NKTR Nektar Therapeutics | 55.39% | 203.08% | 64.60% | -75.00% | -83.27% | -20.53% | -21.26% | -34.32% | -44.96% | 224.74% |
Correlation
The correlation between URGN and NKTR is 0.17, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.17 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.19 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.24 |
Correlation (All Time) Calculated using the full available price history since May 4, 2017 | 0.26 |
Fundamentals
URGN:
$1.76B
NKTR:
$1.63B
URGN:
-$2.73
NKTR:
-$8.64
URGN:
12.15
NKTR:
21.61
URGN:
$140.49M
NKTR:
$55.63M
URGN:
$126.24M
NKTR:
$44.58M
URGN:
-$117.04M
NKTR:
-$121.05M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
URGN vs. NKTR — Risk / Return Rank
URGN
NKTR
URGN vs. NKTR - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for UroGen Pharma Ltd. (URGN) and Nektar Therapeutics (NKTR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| URGN | NKTR | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.66 | ||
| Sortino ratioReturn per unit of downside risk | -4.13 | ||
| Omega ratioGain probability vs. loss probability | 1.32 | 1.77 | -0.45 |
| Calmar ratioReturn relative to maximum drawdown | 3.31 | 14.58 | -11.27 |
| Martin ratioReturn relative to average drawdown | 6.87 | 31.29 | -24.42 |
Loading charts...
Drawdowns
URGN vs. NKTR - Drawdown Comparison
The maximum URGN drawdown since its inception was -93.98%, smaller than the maximum NKTR drawdown of -99.61%. Use the drawdown chart below to compare losses from any high point for URGN and NKTR.
Loading charts...
Drawdown Indicators
| URGN | NKTR | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.98% | -99.61% | +5.63% |
Max Drawdown (1Y)Largest decline over 1 year | -42.22% | -46.54% | +4.32% |
Max Drawdown (3Y)Largest decline over 3 years | -82.64% | -73.20% | -9.44% |
Max Drawdown (5Y)Largest decline over 5 years | -82.64% | -97.76% | +15.12% |
Max Drawdown (10Y)Largest decline over 10 years | — | -99.61% | — |
Current DrawdownCurrent decline from peak | -46.44% | -95.96% | +49.52% |
Average DrawdownAverage peak-to-trough decline | -61.48% | -68.35% | +6.87% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 20.32% | 21.64% | -1.32% |
Volatility
URGN vs. NKTR - Volatility Comparison
The current volatility for UroGen Pharma Ltd. (URGN) is 12.68%, while Nektar Therapeutics (NKTR) has a volatility of 14.13%. This indicates that URGN experiences smaller price fluctuations and is considered to be less risky than NKTR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| URGN | NKTR | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.68% | 14.13% | -1.45% |
Volatility (6M)Calculated over the trailing 6-month period | 44.04% | 60.65% | -16.61% |
Volatility (1Y)Calculated over the trailing 1-year period | 67.38% | 181.99% | -114.61% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 91.62% | 121.87% | -30.25% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 79.43% | 97.20% | -17.77% |
Dividends
URGN vs. NKTR - Dividend Comparison
Neither URGN nor NKTR has paid dividends to shareholders.
Financials
URGN vs. NKTR - Financials Comparison
This section allows you to compare key financial metrics between UroGen Pharma Ltd. and Nektar Therapeutics. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
URGN and NKTR have a correlation of 0.17, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NKTR has higher volatility (14.13%) compared to URGN (12.68%). In terms of maximum drawdown, URGN dropped -93.98% vs NKTR's -99.61%.
NKTR currently has the higher Sharpe Ratio (3.73 vs 2.08), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for URGN and NKTR
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer